Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

Health Investment Returns: Harnessing Health as a Strategic Economic Asset

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy

By HEOR Staff Writer

November 17, 2025

Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy Sacituzumab govitecan for TNBC represents a major step forward in treating untreated